Marseille

• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised
  2022-501562-22-00 4 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised
  2022-502126-40-00 5 HIV-1 infection
• HARMONi-3 Not authorised
  2023-504989-37-00 5 Metastatic Squamous Non-small Cell Lung Cancer
• MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction Not authorised
  2023-507296-21-00 5 Acute Myocardial Infarction
• TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: … Not authorised
  2024-511807-41-00 5 Hemophagocytic lymphohistiocytosis (HLH)
• Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Not authorised
  2024-512754-16-00 5 Prostate cancer
• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Not authorised
  2024-515603-19-00 4 Localized digestive Neuroendocrine Carcinomas
• PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co … Not authorised
  2024-519922-19-00 4 Neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin
• A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Tr … Not authorised
  2025-523820-26-00 5 Growth Hormone Deficiency (GHD)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• Stroke in childhood due to inflammatory narrowing of blood vessels: Treatment with steroids Pending
  2022-500631-36-00 5 Focal cerebral arteriopathy and childhood stroke Focal cerebral arteri
• Methotrexate treatment in hand osteoarthritis refractory to usual treatments Pending
  2022-502362-24-00 4 Erosive osteoarthritis
• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat … Pending
  2022-502365-26-00 5 Asthma
• A study to assess the long-term safety and clinical activity of mRNA-3927 in participants previously enrolled in the mRNA-3927-P101 study Pending
  2022-502911-12-00 9 Propionic Acidemia
• Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Pending
  2023-505750-17-00 4 Neovascular age-related macular degeneration
• Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis r … Pending
  2023-506420-93-00 4 Chronic recurrent multifocal osteomyelitis (CRMO)
• CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patient … Pending
  2023-507010-27-00 5 Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cu
• Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee os … Pending
  2023-507683-40-00 5 knee osteoarthritis
• Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo … Pending
  2023-508658-24-00 4 type B3 thymoma and thymic carcinoma
• Efficacy and tolerance of nicotinamide supplementation during acute kidney injury: a prospective randomized double-blind trial Pending
  2023-508664-30-00 5 Acute kidney injury

Showing 1–24 of 1,485 trials